Compare Moderna, Inc. (MRNA) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Sony Group Corp — how do they compare? Moderna, Inc. trades at $62.23 (market cap $24.18B), while Sony Group Corp trades at $23.41 (market cap $138.43B). The key difference: Sony Group Corp is far larger — about 5.7× Moderna, Inc.'s market cap, and Sony Group Corp pays a 0.67% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SONY | |
|---|---|---|
Market Cap | $24.18B | $138.43B |
Sector | Health | Technology |
52-Week High | $81.80 | $30.26 |
52-Week Low | $22.36 | $19.32 |
Enterprise Value | $20.33B | $136.35B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Sony (SONY) trades at $23.82, up 1.53% over the past day, with a bullish technical signal from moving averages and oscillators. Recent earnings show mixed quarterly results, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. The company reported strong operating cash flow of $2.32 trillion in 2025, though net income margin turned negative at -1.75% for 2026. Positive sentiment is driven by blockbuster Spider-Man performance and a joint venture with TSMC for image sensors.
The outlook is cautiously optimistic, supported by analyst consensus with 68.75% buy ratings and a 29.75% upside potential. Key opportunities include growth in gaming and sensors, while risks involve profitability pressures and competitive threats. Investors should weigh strong cash flow against margin volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
